Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the <scp><i>BRAF</i> V600E</scp> mutation with high expression of <scp>PD‐L1</scp>: A case report-Reference-Cited by-同舟云学术

Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD‐L1: A case report

Published:2024-03 Issue:11 Volume:15 Page:929-933
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Inoue Takako¹^ORCID,Kunimasa Kei¹^ORCID,Tamiya Motohiro¹,Kawamura Takahisa¹,Minami Toshiyuki²³,Nishino Kazumi¹

Affiliation:

1. Department of Thoracic Oncology Osaka International Cancer Institute Osaka Japan

2. Department of Respiratory Medicine and Hematology Hyogo Medical University Nishinomiya Japan

3. Department of Thoracic Oncology Hyogo Medical University Kobe Japan

Abstract

AbstractWe present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progression on immunotherapy. This case may provide an opportunity for clinicians to consider the order of administration of immunotherapy and molecular targeted therapy for BRAF V600E‐positive lung cancer.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.15254

Reference9 articles.

1. Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

2. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

3. US Food and Drug Administration. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation 2023. Accessed 24 November 2023.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐accelerated‐approval‐dabrafenib‐combination‐trametinib‐unresectable‐or‐metastatic‐solid./

4. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

5. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer